2025-04-07 09:40
Notice of Annual General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414’s potential to reduce gastrointestinal-related...
The Annual Report including Corporate Governance Report for 2024 is available on IBT´s website, www.ibtherapeutics.com under the section "Investors...
2025-02-13 08:30
Infant Bacterial Therapeutics AB (publ) Year-end report January 1 – December 31, 2024
Message from the CEO The scientific literature suggests that benign bacteria of the type found in IBT's drug product IBP-9414 can positively affect the...
2024-12-20 16:33
IBT Continues Development of Drug Candidate IBP-9414
IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase...
2024-11-14 08:30
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Message from the CEO This quarter, IBT completed the global Phase 3 clinical trial “The Connection Study” for the drug candidate IBP-9414...
2024-10-23 09:00
Infant Bacterial Therapeutics to present at FDA workshop in the USA
Infant Bacterial Therapeutics has been invited to present at the event “Live Biotherapeutic Products to Prevent Necrotizing Enterocolitis in Very...
2024-10-09 09:00
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2025
The 2024 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
2024-09-01 19:27
IBT invites you to a virtual meeting/call on Tuesday, September 3rd, 2024, at 4 pm CET, to discuss the recent results from the Connection Study.
The following topics are planned to be commented on during the call: Join the video meeting by clicking this link: https://meet.google.com/jmy-cdhn-wwo.You...
2024-08-30 18:38
IBT's phase III study shows no significant effects on the primary endpoints but a significant reduction in the secondary endpoint, all-cause mortality
IBT has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug...